Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 August 2021 | Story Ruan Bruwer | Photo Varsity Sports
The UFS celebrates its 55-39 win over Stellenbosch University in the final of the Varsity Netball tournament. This is their fourth crown in eight years.

After losing to Stellenbosch University in the opening round of Varsity Netball, the University of the Free State (UFS) kept the trust and smashed the same opponents eight days later to lift the trophy.

The UFS netball team claimed their fourth crown – two more than any other team in the eight years of the competition – when they won the final by 55-39 in Stellenbosch on Monday night (30 August 2021).

This is the biggest victory margin in a final. The UFS team has now won all four finals in which they participated.
According to coach Burta de Kock, she did not say much to the players after their first-round loss by eight goals. It was their only defeat in nine matches.

“I left them alone and I knew they would fix what had to be fixed. We kept the trust the whole time.”

“The players promised one another before the final that they would bring their best to the court. We are blessed to have such wonderful players taking the lead and guiding and mentoring the youngsters,” De Kock said.

Captain Sikholiwe Mdletshe also mentioned the first encounter as the turning point. “We got the team together and decided to fight as an army. We never looked back.”

Khanyisa Chawane, who was the Player of the Match in both the final and semi-final, said, “We told ourselves we are going to a final and we are going to win it, and that is the mindset we came here with and what took us through.”

Prof Francis Petersen, UFS Rector and Vice-Chancellor, congratulated the champions. “Under the leadership of coach Burta de Kock and captain Sikholiwe Mdletshe, the team worked exceptionally hard to reach the top, and their commitment and courage paid off.” 

“Thank you also to the rest of the coaching staff. The final was spectacular, and we are proud of what they have achieved. I salute our champions on behalf of the entire university community,” Prof Petersen said.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept